Related Experiment Video
Updated: Apr 20, 2026
A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
Published on: October 20, 2016
Preliminary results on CSF biomarkers for hypothalamic dysfunction in Kleine-Levin syndrome
Régis Lopez1, Lucie Barateau2, Sofiene Chenini2
1Service de Neurologie, Hôpital Gui-de-Chauliac, CHU, Montpellier, France; Centre de Référence Nationale Maladie Rare, Narcolepsie et Hypersomnie Idiopathique, Montpellier, France; Inserm U1061, Montpellier, France.
Objective:
To measure CSF biomarkers of hypothalamic dysfunction in patients with typical Kleine-Levin syndrome (KLS) during symptomatic and asymptomatic periods.
Patients/Methods:
Two patients with typical KLS were admitted during symptomatic and asymptomatic periods to a research Sleep Disorders Center. Cerebrospinalfluid (CSF) hypocretin-1, histamine (HA), and its major metabolite tele-methylhistamine (t-MHA) levels were measured in two KLS patients in and out of episode.
Results:
CSF biomarkers of hypothalamic dysfunction measured in two KLS patients in and out of episode revealed low hypocretin levels (within the narcolepsy-cataplexy range) during a hypersomnia episode in the more severe patient, and a 42% decrease (although within normal range) in the second patient. CSF HA and t-MHA measurements in and out of episode revealed a two-fold in-episode decrease in HA in the more severe patient, with no significant change for the second patient, nor for t-MHA levels.
Conclusion:
We reported reversible changes in CSF hypothalamic biomarkers in a typical patient with KLS that reinforces the hypothesis that in some patients KLS episodes may be caused by recurrent functional alterations of the hypothalamus.
